CANNPICO

Cosmetics and cosmetic preparations, none of the foregoing comprised of Cannabis sativa L with a delta-9 tetrahydrocannabinol (THC) content of more than 0.3 percent on a dry weight basis

Pharmaceuticals for the treatment of anxiety, including post-traumatic stress disorder, epilepsy, schizophrenia and other psychiatric disorders, chronic and neuropathic pain, neurodegenerative disorders, tumors, diabetes, movement disorders and anti-spastic treatment, drug abuse, including withdrawal treatment, COVID-19 related lung inflammation, oxidative stress, and skin diseases; none of the foregoing comprised of Cannabis sativa L with a delta-9 tetrahydrocannabinol (THC) content of more than 0.3 percent on a dry weight basis

Wholesale services, namely, ordering services and direct solicitation by sales agents and distributors for pharmaceutical, cosmetics and cosmetic preparations with none of the foregoing comprised of Cannabis sativa L with a delta-9 tetrahydrocannabinol (THC) content of more than 0.3 percent on a dry weight basis; advertising services in relation to cosmetics, cosmetic preparations, and pharmaceuticals